Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
A team of researchers from NYU has demonstrated that the key to understanding working memory relies not only on what one is storing in memory, but also why.
The Noelin family of secreted proteins bind to the external portion of AMPA glutamate receptors and stabilize them on the neuronal cellular membrane, a process necessary for transmission of full-strength signals between neurons.
“Visual-movement” neurons in the front of your brain can help you stay focused in the presence of visual distractions, according to a new study from neuroscientists in the Perelman School of Medicine at the University of Pennsylvania.
New York University researchers have discovered new cell types in the visual system of flies, made possible by their creation of a tool that finds and labels neurons during development.
Missouri S&T researchers have developed a treatment that could eventually enable glaucoma patients to only use eye drops once per week instead of daily, and it should also be more effective.
Designed by researchers at NYU, Commute Booster routes public-transportation users through the “middle mile” — the part of a journey inside subway stations or other similar transit hubs.
SUNY College of Optometry’s Dr. Alexandra Benavente-Pérez was awarded a grant that will explore the unknown nature of the relationship between myopia (nearsightedness) and glaucoma by focusing on their effect on the ganglion cell complex.
Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years